Clinical Trials Logo

Filter by:
NCT ID: NCT00815542 Not yet recruiting - Cervical Ripening Clinical Trials

Induction of Labor in Oligohydramnios

Start date: June 2012
Phase: Phase 3
Study type: Interventional

When oligohydramnion - decreased amniotic fluid, is diagnosed at term pregnancies, the common practice is to induce labor. Whenever the cervix is not ripened, there are several methods to ripen the cervix, two of which are: mechanical, using a double balloon catheter and pharmacological, with prostaglandins. The aim of the study is to compare those two methods of cervical ripening for patients with significant oligohydramnion at term. The study will be a prospective randomised trial.

NCT ID: NCT00815516 Terminated - Candidiasis Clinical Trials

Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis

MAGIC-2
Start date: February 2013
Phase: Phase 3
Study type: Interventional

The study will evaluate how effective and how safe the drug micafungin is when compared to the drug amphotericin B deoxycholate in treating neonates and young infants with certain fungal infections.

NCT ID: NCT00815373 Withdrawn - Ocular Hypertension Clinical Trials

The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG)

Xal-Cos
Start date: December 2008
Phase: N/A
Study type: Interventional

Both Cosopt® and Xalatan® plus Timoptic® will significantly lower IOP, however only Cosopt® will demonstrate positive hemodynamic effects. The clinical significance of this will be investigated by examining the ophthalmic and short posterior ciliary arteries to determine the blood supply to the optic nerve head, the site of damage in glaucoma

NCT ID: NCT00815113 Completed - Gastric Cancer Clinical Trials

Screening for Gastric Cancer in High-risk Population

Stomach
Start date: October 2009
Phase:
Study type: Observational

Introduction: Gastric cancer is the world's second largest cause of cancer related deaths. In the Western world, as well as in Israel, this malignancy is less prevalent than colorectal cancer, but has higher morbidity and mortality. First degree relatives of patients with gastric cancer have a 1.5-fold to 3-fold increased risk of developing gastric cancer themselves. In relatives of gastric cancer patients who are also carriers of a CagA positive strain of Helicobacter pylori, the risk is 8-fold. Mucosal atrophy, hypochlorhydria, high lymphoid follicle density, pan gastritis, and interleukin 1 β polymorphism are frequent in family members of gastric cancer patients and are associated with increased risk of the disease. Aims: 1. To characterize the high risk individual for gastric cancer development. 2. To establish a screening plan for early detection and prevention of gastric cancer in first degree relatives of gastric cancer patients. 3. To validate new procedures for assessing risk factors for development of gastric cancer: gastric acid output, gastric mucin output, serum levels of pepsinogen I, pepsinogen II, gastrin B12, Helicobacter pylori status [serology, histology, urease test, 13C-urea breath test (13C-UBT)]. 4. To assess genetic changes in the gastric mucosa of the screenees in comparison with gastric cancer patients and controls. Methods: We will approach 50 gastric cancer patients treated in Rabin Medical Center, and ask for their consent to approach first degree relatives for participating in the study. For each gastric cancer patient 4 relatives will be asked to signed an informed consent and undergo the study procedures. For each participant a matched control for age, sex and background diseases, out of consecutive gastro esophageal reflux disease (GERD) patients undergoing gastroscopy, will be asked to join the study. Thus, we will screen 50 gastric cancer patients, 200 first degree relatives of gastric cancer patients, and 200 controls.

NCT ID: NCT00815061 Withdrawn - Ulcerative Colitis Clinical Trials

Epidemiology of Ulcerative Colitis and Crohn's Disease in Non Jewish Israel Population

Start date: July 2008
Phase: N/A
Study type: Observational

The aim of the present study was to describe the incidence and prevalence of IBD in non Jewish Israel population

NCT ID: NCT00814814 Active, not recruiting - Clinical trials for Cardiopulmonary Arrest Outcome

Protein S100 Beta as a Predictor of Resuscitation Outcome

Start date: February 2008
Phase:
Study type: Observational

Management of cardiac arrest is complicated by the lack of a readily available tool identifying individuals who are likely to be successfully resuscitated. S100 beta is a protein that originates in the astroglial cells of the brain, and NSE (Neuron Specific Enolase) is another protein that originates in the neurons themselves. In the laboratory, the concentration of these proteins correlate with evidence of brain damage after head trauma, stroke and exposure to low levels of oxygen. The concentration of these proteins in the blood of human survivors of cardiopulmonary resuscitation in humans is much higher than in patients who were resuscitated but did not survive. However, it is still unclear whether survivors from cardiopulmonary resuscitation have higher levels of these proteins in their blood if they survive with neurological injury secondary to the arrest and resuscitation. Hypothesis: In humans, the blood concentrations of protein S100 beta and NSE during and after resuscitation can predict who will die despite cardiopulmonary resuscitation and who will survive with neurological injury secondary to the arrest and resuscitation.

NCT ID: NCT00814476 Completed - Type 1 Diabetes Clinical Trials

The Effects of Regular Home Use Vs Diabetic Team- Supported Use of the Medtronic CareLink Therapy Management System.

CareLink
Start date: January 2009
Phase: Phase 4
Study type: Interventional

Randomized, two arms, controlled, open study comprised of two consecutive segments. At the first segment that will last during the first 4 months of the study, patients will be randomized to the Care link treated group or non Care link treated group. At this segment of the study the usage of the Care link system will be accompanied by the diabetic team, through at least monthly contact via the Internet initiated by the diabetic team. At the second segment of the study, during the following 4 months, both groups will use the Care link System, home-use, without support initiated by the diabetic team.

NCT ID: NCT00814450 Completed - Biopsy Clinical Trials

Safety & Accuracy of the ActiSight Needle Guidance System in Percutaneous Chest Aspiration and Biopsy

ANGS-PCAB
Start date: December 2008
Phase: N/A
Study type: Interventional

This study is intended to provide clinical data regarding safety and accuracy of the ActiSight™ Needle Guidance System in assisting Chest CT guided biopsies.

NCT ID: NCT00814424 Not yet recruiting - Clinical trials for Ventilatory Status of Deeply Sedated ERCP Patients

Quantitive And Qualitive Assessment Of The Oxygen Delivery And EtCO2 Sampling With The Smart Bite Block Mark III During An Upper Endoscopic Procedure Under Sedation

Start date: January 2009
Phase: N/A
Study type: Interventional

The study hypothesis is that a modified smart bite block system can deliver up to 10 liters/minute of supplemental oxygen orally with the CO2 monitoring performance substantially equivalent to the currently marketed smart bite block that delivers oxygen up to 5 liters/minute

NCT ID: NCT00813709 Completed - Multiple Sclerosis Clinical Trials

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)

REFLEXION
Start date: December 2008
Phase: Phase 3
Study type: Interventional

REFLEXION is a double blind extension of the study 27025 (NCT00404352) (REFLEX). The purpose of the study is to obtain long-term follow-up data in subjects with clinically definite multiple sclerosis (MS) and subjects with a first demyelinating event at high risk of converting to MS, treated with fetal bovine serum [FBS]-free/human serum albumin [HSA]-free formulation of interferon [IFN]-beta-1a (RNF).